Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting

[at noodls] – Sotatercept produces dose dependent increases in hemoglobin with no dose dependent changes in blood pressure CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical … more

View todays social media effects on CELG

View the latest stocks trending across Twitter. Click to view dashboard

See who Celgene is hiring next, click here to view